Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton’s tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting

Saved in:
Bibliographic Details
Published in:Journal of managed care & specialty pharmacy 2024-07, p.1-11
Main Authors: Huntington, Scott F., Manzoor, Beenish S., Jawaid, Dureshahwar, Puckett, Justin T., Emechebe, Nnadozie, Ravelo, Arliene, Kamal-Bahl, Sachin, Doshi, Jalpa A.
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2376-0540
2376-1032
DOI:10.18553/jmcp.2024.24049